Canaccord Genuity analyst Max Masucci maintained a Buy rating on Natera (NASDAQ:NTRA) on Tuesday, setting a price target of $72, which is approximately 13.01% above the present share price of $63.71.
Masucci expects Natera to post earnings per share (EPS) of -$0.45 for the third quarter of 2020.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in Natera, with an average price target of $66.
The analysts price targets range from a high of $75 to a low of $60.
In its latest earnings report, released on 03/31/2020, the company reported a quarterly revenue of $94.01 million and a net profit of -$34.87 million. The company's market cap is $5.09 billion.
According to TipRanks.com, Canaccord Genuity analyst Max Masucci is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 44.2% and a 75.00% success rate.
Natera, Inc. engages in the discovery, development, and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test, Horizon Carrier Screening, Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis, Anora Products of Conception and Non-Invasive Paternity Testing. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in San Carlos, CA.